Experience in treating patients with autoimmune pancreatitis

Authors

DOI:

https://doi.org/10.30978/GS-2024-3-9

Keywords:

autoimmune pancreatitis, type 1 AIP, type 2 AIP, IgG4‑related pancreatitis

Abstract

Objective — to establish the main diagnostic signs of autoimmune pancreatitis and aspects of patient treatment.

Materials and methods. The study analyzed the results of examination and treatment of 17 patients with autoimmune pancreatitis (AIP) from 2010 to 2022. Among the total number of patients with AIP, there were 11 men (65%) and 6 women (35%). The average age of the patients was 52.4 years. Among all patients with AIP, focal involvement of the pancreas was found in 3 (18%) patients, with a predominant involvement of the head of the pancreas. Segmental form of AIP was diagnosed in 6 (35%) patients, while diffuse form was found in 8 (47%) patients. Type 1 AIP was identified in 13 (76%) patients, and type 2 AIP in 4 (24%) patients. For all patients suspected of AIP, the HISORt criteria were assessed: instrumental visualization, serological and histological verification, determination of the volume of pancreatic involvement, and response to steroid therapy.

Results. Recurrence of AIP was observed in 8 (47.0%) patients with type 1 AIP and 1 (5.8%) patient with type 2 AIP. AIP recurred in patients with proximal bile duct involvement, diffuse pancreatic involvement, persistently elevated IgG4 levels after steroid induction, delayed radiological remission, and damage to more than two organs. Increased serum levels of IgG, IgG4, apnd eosinophilia indicated a recurrence of IgG4‑RD. A repeat induction of steroids was performed in patients with recurrent AIP, which proved to be very effective, resulting in high remission rates, specifically in 7 (70%) patients with type 1 AIP and in 1 (100%) patient with type 2 AIP. Among all AIP patients that were operated on, 3 (40%) underwent Roux‑en‑Y hepaticojejunostomies, 1 (20%) pancreaticoduodenectomy, and 1 (20%) a Frey procedure.

Conclusions. The low incidence of AIP necessitates the use of a clear diagnostic algorithm, and the peculiarities of the disease’s course require compliance with all the principles of conservative treatment and surgical interventions in case of surgical complications.

 

References

Blaho M, Dítě P, Kunovský L, et al. Autoimmune pancreatitis — An ongoing challenge. Adv Med Sci. 2020;65(2):403-8. http://doi.org/10.1016/j.advms.2020.07.002. PMID: 32805624.

Beyer G, Habtezion A, Werner J, Lerch MM, Mayerle J. Chronic pancreatitis. The Lancet. 2020;396(10249):499-512. http://doi.org/10.1016/S0140-6736(20)31318-0. PMID: 32798493.

Chari ST, Kloppel G, Zhang L, et al. The autoimmune pancreatitis International cooperative study group (APICS). Histopathologic and clinical subtypes of autoimmune pancreatitis: The Honolulu consensus document. Pancreas. 2010;39:549-54. http://doi.org/10.1097/MPA.0b013e3181e4d9e5. PMID: 20562576.

Kamisawa Terumi. Epidemiology of autoimmune pancreatitis. In The Pancreas: An Integrated Textbook of Basic Science, Medicine, and Surgery. 2023. P. 533-539. http://doi.org/10.1002/9781119876007.ch68.

Kamisawa T, Takeuchi T. Treatment of autoimmune pancreatitis with the anecdotes of the first report. Int J Rheum. 2012;2012:597643. http://doi.org/10.1155/2012/597643. PMID: 22548071; PMCID: PMC3323841.

Ketwaroo GA, Sheth S. Autoimmune pancreatitis. Gastroenterol Rep. (Oxf.). 2013;1(1):27-32. http://doi.org/10.1093/gastro/got011. PMID: 24759664; PMCID: PMC3768278.

Khandelwal A, Inoue D, Takahashi N. Autoimmune pancreatitis: an update. Abdom Radiol. (NY). 2020;45(5):1359-70. http://doi.org/10.1007/s00261-019-02275-x. PMID: 31650376.

Kim KP, Kim MU, Song MH, et al. Autoimmune chronic pancreatitis. Am J Gastroenterol. 2004;99:1605-16. http://doi.org/10.1111/j.1572-0241.2004.30336.x. PMID: 15307882.

Kubo K, Yamamoto K. IgG4-related disease. Int J Rheum Dis. 2016;19(8):747-62. http://doi.org/10.1111/1756-185X.12586. PMID: 26259069.

Li A, Wang Y, Deng Zh. Concurrent autoimmune pancreatitis and primary biliary cirrhosis: a rare case report and literature review. BMC Gastroenterol. 2014;14:10. http://doi.org/10.1186/1471-230X-14-10. PMID: 24410827; PMCID: PMC3897989.

Liu C, Zhang P, Zhang W. Immunological mechanism of IgG4-related disease. J Transl Autoimmun. 2020;3:100047. http://doi.org/10.1016/j.jtauto.2020.100047. PMID: 32743528; PMCID: PMC7388377.

López-Serrano A, Crespo J, Pascual I, et al. Diagnosis, treatment and long-term outcomes of autoimmune pancreatitis in Spain based on the International Consensus Diagnostic Criteria: A multi-centre study. Pancreatology. 2016;16(3):382-90. http://doi.org/10.1016/j.pan.2016.02.006; PMID: 26944001.

Mari A, Kadah A, Mahamid M, et al. IgG4 related autoimmune pancreatitis: an overview and the emerging role of serum eotaxin as a potential treatment target. Isr Med Assoc J. 2019;21(9):620-3. PMID: 31542909.

Maruyama M, Watanabe T, Kanai K, et al. International Consensus Diagnostic Criteria for Autoimmune Pancreatitis and its Japanese amendment have improved diagnostic ability over existing criteria. Gastroent Res Pract. 2013;2013:456965. http://doi.org/10.1155/2013/456965. PMID: 24348535; PMCID: PMC3857831.

Meng Q, Xin L, Liu W, et al. Diagnosis and treatment of autoimmune pancreatitis in China: A systematic review. PLoS One. 2015;10(6):e0130466. http://doi.org/10.1371/journal.pone.0130466. PMID: 26110658; PMCID: PMC4481503.

Minaga K, Watanabe T, Hara A, et al. Plasmacytoid dendritic cells as a new therapeutic target for autoimmune pancreatitis and IgG4-related disease. Front Immunol. 2021;12:713779. http://doi.org/10.3389/fimmu.2021.713779. PMID: 34367181; PMCID: PMC8342887.

Nishimori I, Tomakoshi A, Olsuki MJ. Prevalence of autoimmune pancreatitis in Japan from a nationwide survey in 2002. Gastroenterology. 2007;42(18):6-8. http://doi.org/10.1007/s00535-007-2043-y. PMID: 17520216.

Notohara K, Burgart LJ, Yadav D, Chari S, Smyrk TC. Idiopathic chronic pancreatitis with periductal lympho- plasmacytic infiltration: clinicopathologic features of 35 cases. Am J Surg Pathol. 2003;27(8):1119-27. http://doi.org/10.1097/00000478-200308000-00009. PMID: 12883244.

Omiyale AO. Autoimmune pancreatitis. Gland Surg. 2016;5(3):318-26. http://doi.org/10.21037/gs.2015.11.02. PMID: 27294040; PMCID: PMC4884700.

Pezzilli R, Pagano N. Pathophysiology of autoimmune pancreatitis. World J Gastrointest. Pathophysiol. 2014;5(1):11-7. http://doi.org/10.4291/wjgp.v5.i1.11. PMID: 24891971; PMCID: PMC4024516.

Sarles H, Sarles JC, Muratore R, Guien C. Chronic inflammatory sclerosis of the pancreas — an autonomous pancreatic disease? Am J Dig Dis. 1961;6:688-98. http://doi.org/10.1007/BF02232341. PMID: 13746542.

Shimosegawa T, Chari ST, Frulloni L, Kamisawa T, Kawa S, Mino-Kenudson M, Kim MH, Kloppel G, Lerch MM, Lohr M, Notohara K, Okazaki K, Schneider A, Zhang L. International Association of Pancreatology. International consensus diagnostic criteria for autoimmune pancreatitis: guidelines of the International Association of Pancreatology. Pancreas. 2011;40(3):352-8. http://doi.org/10.1097/MPA.0b013e3182142fd2. PMID: 21412117.

Simone R, Pesce G, Antola P, et al. The soluble form of CTLA-4 from serum of patients with autoimmune diseases regulates T-cell responses. Biomed Res Int. 2014;2014:215763. http://doi.org/10.1155/2014/215763. PMID: 24605322; PMCID: PMC3925529.

Takuma K, Kamisawa T, Gopalakrishna R, et al. Strategy to differentiate autoimmune pancreatitis from pancreas cancer. World J Gastroenterol. 2012;18(10):1015-20. http://doi.org/10.3748/wjg.v18.i10.1015. PMID: 22416175 PMCID: PMC3296974.

Trampert DC, Hubers LM, van de Graaf SFJ, et al. On the role of IgG4 in inflammatory conditions: lessons for IgG4-related disease. Biochim Biophys Acta Mol Basis Dis. 2018;1864(4 Pt B):1401-9. http://doi.org/10.1016/j.bbadis.2017.07.038. PMID: 28782655.

Yang X-C, Fujino M, Cai S-J, et al. Genetic polymorphisms of cytotoxic T-lymphocyte antigen 4 in primary biliary cholangitis: a meta-analysis. J Immunol Res. 2017;2017:5295164. http://doi.org/10.1155/2017/5295164. PMID: 28642883; PMCID: PMC5470032.

Zhou Q, Tao X, Xia S, et al. T lymphocytes: a promising immunotherapeutic target for pancreatitis and pancreatic cancer? Frontiers. Oncology. 2020;10(382). http://doi.org/10.3389/fonc.2020.00382. PMID: 32266154; PMCID: PMC7105736.

Downloads

Published

2024-10-08

How to Cite

1.
Dronov O, Bakunets Y, Prytkov F. Experience in treating patients with autoimmune pancreatitis. ЗХ [Internet]. 2024Oct.8 [cited 2024Dec.8];(3):9-13. Available from: http://generalsurgery.com.ua/article/view/314648

Issue

Section

Original Research